Since 1999, there has been a 40 percent increase per year in the number of breast MR studies performed in the United States. In addition, over 1200 sites in the United States have purchased surface coils for use in breast MR. This number is expected to grow to over 2,000 coils by the end of 2007.
Introduction

Indications for Breast MR
Much of the demand for breast MR is driven by breast surgeons in need of accurate staging information but indications for use have recently expanded to include screening women at high-risk (1). In May 2003, the American Cancer Society released updated guidelines on breast cancer screening, recommending MRI as an effective and sensitive imaging adjunct to mammography and ultrasound (2).
Breast MR Acquisition
In 1986 Heywang et al. (3) , showed that essentially all invasive breast malignancies enhance with after injection of gadolinium contrast. Dynamic contrastenhanced MRI studies were then described in 1989 by Kaiser (4) , and it was later shown that enhancement rate and signal intensity behavior in late post-injection phases both convey diagnostically useful information (5).
Chris Wood, M.S. Confirma, Inc. 821 Kirkland Avenue Kirkland, WA 98033, USA Dynamic contrast-enhanced breast MR is performed using 3D image acquisition techniques. In 60 to 90 seconds, slices covering all the breast tissue (typically both breasts) can be acquired at resolution of 1 mm or smaller. The first 3D acquisition is followed by the injection of the contrast agent, then several additional 3D acquisitions. The dynamic information is captured in less than nine minutes after the injection. Image acquisition protocols that capture the early and late post-contrast kinetics (enhancement profile) are the current standard of care. The same images may be used for morphological interpretation, or additional "high resolution" series may be added to the study.
Breast MR Interpretation
Many published studies have validated enhancement rate and washout behavior as key features that are correlated with malignancy (6) . When combined with morphological interpretation, it has been shown that a sensitivity of 92% with a specificity of 92% is possible (7).
The most accepted and validated list of features correlated with malignancy are captured in the BI-RADS ® ATLAS (8). Breast MR was included in the atlas for the first time in 2003. According to the BI-RADS ® committee, "…it is important to evaluate a finding on both morphologic and kinetic characteristics." The guidance provided by BI-RADS ® for interpretation of kinetics is qualitative instead of quantitative.
Section F of the BI-RADS ® Lexicon focuses on kinetic curve assessment and reporting. The features used in the BI-RADS ® Lexicon to characterize curve kinetics are listed below:
• Initial phase (first 2 minutes) -slow -medium -rapid • Delayed phase (after 2 minutes) -persistent -plateau -washout Figure 1 shows the guidelines for the two-phase (initial and delayed) evaluation technique described by the BI-RADS ® ATLAS. To interpret breast MR studies using the BI-RADS ® criteria, enhancing regions need to be visually identified (typically using subtractions) and delayed enhancement is typically assessed using time/intensity curves.
CAD for Breast MR
CAD has been defined as "…the discovery of features that may be related to malignancy" (9). CAD for X-Ray mammography was the first CAD application to gain FDA approval, and like CAD for mammography, CAD for breast MR highlights features correlated with malignant breast lesions. Upon closer inspection however, at least three fundamental differences between CAD for X-Ray mammography and CAD for breast MR emerge. These differences are summarized in Table I .
Given these differences, CAD for breast MR can be defined as:
The automated analysis of enhancement kinetics, highlighting features related to malignancy Acquisition protocols change frequently due to innovation in pulse sequence, coil, and acquisition hardware capabilities. Differences in acquisition protocols between sites are driven by the differing capabilities of commercial MR systems and differing physician preferences. Consequently, CAD systems need to be designed to be flexible enough to adapt to protocol changes and site differences. 
Materials and Methods
BI-RADS ® ATLAS-Based Interpretation of Curve Kinetics
CAD systems help the physician interpret breast MR by automating extraction and interpretation of curve kinetics. Figure 2 shows where CAD contributes to interpretation of a breast MR.
Using a BI-RADS ® -based CAD system, curve extraction and thresholding result in angiogenesis maps, which standardize the interpretation of breast MR according to the BI-RADS ® ATLAS. Figure 3 shows how colors are used to map areas of enhancement and encode washout behavior. Figure 4 shows a sample angiomap with colors indicating washout behavior. Color coding provides a quick way for radiologists to find areas of significant enhancement and assess their late contrast behavior.
Many factors contribute to the selection of thresholds and curve extraction. Some of these factors are described below. Curve is "flattened" as acquisition time increases so the threshold must be lowered. • Toggle medium and fast labeling on and off • Six colors indicate medium (persistent, plateau, washout) and fast (persistent, plateau, washout) 
Contrast Dose and Injection
Unregistered subtraction
Register Subtraction thresholds of 50% and 100% (7) and a dose of 0.2 mmol/kg with corresponding thresholds of 70% and 140% (11) have both proven to result in high accuracy.
Temporal and Spatial Resolution: Low spatial resolution can affect contrast kinetics for small lesions through partialvolume artifact. Lesions as small as 2 mm can enhance significantly, but slice thicknesses as high as 3 mm are still used clinically. Partial volume artifact will reduce the measured enhancement and thresholds should be lowered.
As temporal resolution is reduced, rapid changes in signal enhancement can be lost due to a low sampling rate. Figure  5 shows the effect on the measured curve when reducing temporal resolution.
Sampling Around Peak Contrast Concentration:
Ideally, the center of k-space should be acquired coincident with the peak concentration of contrast in the tumor. If contrast concentration peaks between scans, the measured percent enhancement is reduced. Since contrast flows into a tumor faster than it washes out, even the slightest delay in sampling provides more room for error.
Patient Movement: Patient movement during a volume acquisition results in blurring of the image data. This causes an artifact similar to partial volume artifacts in that the signal is spread out instead of concentrated in a few voxels.
Patient movement between acquisitions causes voxel misalignment which results in inaccurate curves and the introduction of "pseudo lesions." Correction for patient movement between scans is possible through non-rigid registration techniques (12). One study resulted in a reduction of pseudolesions in 92% of the cases, while not introducing any false negatives (13). Figure 6 shows the difference in subtraction images computed with, and without registration correction.
Region of Interest (ROI) Size:
The ROI size is an important factor to consider. If the ROI is too big, the heterogeneity of the tumor corrupts the result. If the ROI is too small, image noise may corrupt the result (14). The BI-RADS ® ATLAS recommends that a ROI no smaller than 3 pixels should be used.
ROI Placement:
Fortunately, subjective interpretation of these curves has been shown to result in agreement between observers (15). Disagreement does occur, however, when users are allowed to select their own ROI location. Manual ROI selection has resulted in up to 29% disagreement between observers (16). However, when computerized search methods are used, disagreement is eliminated and up to 38% increase in detection of washout curves is observed (17).
Image Signal to Noise: Curves are displayed as percent enhancement. Parallel imaging techniques [ASSET (array spatial and sensitivity encoding technique), iPAT (integrated parallel acquisition techniques), SENSE (sensitivity encoding)] can increase spatial resolution without trading off temporal resolution, but a signal-to-noise penalty needs to be considered when viewing contrast kinetics. Decreasing signal to noise may result in false positives due to random noise.
Field Strength: Breast MR for diagnostic purposes is generally performed at 1.0 and 1.5T. All other factors being equal, higher field strength results in greater enhancement.
Alternative Interpretation of Curve Kinetics -Pharmacokinetic Modeling
If one assumes that tissue and vascular spaces can be modeled as two compartments, contrast media concentration vs. time can be derived from signal intensity vs. time. From the contrast media concentration, hemodynamic parameters such as microvascular permeability and extracellular volume fraction can then be estimated.
The two-compartment model assumption, however, may be invalid (18), particularly in tumors, resulting in poor fits and unreliable results (19) . Concentration calculation requires measurements of the change in T1 following contrast injection, which is a time consuming exercise. Also, significant errors may be introduced because of the incorrect arterial input functions used in the model (20).
While contrast kinetics are important, a local increase in vascularity and/or capillary permeability is not specific for malignant tissues: almost all benign neoplastic lesions, and many benign non-neoplastic states can exhibit variable contrast enhancement (21).
Mapping pathophysiological features of breast tumors using pharmacokinetic modeling and a two compartment model is still under investigation. The validity of this model and potential clinical benefit can only be determined through continued investigation.
Discussion
Computer aided detection (CAD) algorithms that automate some of the interpretation tasks for the physician result in efficiency gains. It has also been shown that using CAD for breast MR may help to reduce false positives (22).
The simple presence or absence of contrast enhancement, or the type of contrast enhancement, is not sufficient to either confirm or exclude the presence or absence of malignancy in breast MRI. Morphological, clinical, mammo-graphic, and sonographic data should be used in conjunction with contrast kinetics to improve detection and differentiation of lesions by dynamic breast MRI.
The kinetic features with the most clinical validation have been chosen by the ACR and included in the BI-RADS lexicon. These features have served as the guidance for the algorithms behind the CADstream angiogenesis maps. CADstream angiogenesis maps provide a fast and reproducible way to take images from nearly any breast MR acquisition protocol and highlight features correlated with malignancy. This results in more efficient breast MRI interpretation.
Looking forward, CAD for breast MR will include additional analysis of contrast kinetics, but perhaps more importantly, quantitative analysis of morphological features. The combination of both quantitative contrast kinetics and morphology data will allow radiologists to make more "evidence based" decisions regarding management of suspicious lesions observed in breast tissue. When multiple breast modalities are combined, accuracy may increase even further. These improvements in CAD for breast MR will help enable custom screening protocols designed specifically for a patient's risk level. These individually optimized screening protocols have the potential to reduce mortality from breast cancer in the high-risk population.
